http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Luquero, Francisco J (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
Bi, Qifang,Ferreras, Eva,Pezzoli, Lorenzo,Legros, Dominique,Ivers, Louise C,Date, Kashmira,Qadri, Firdausi,Digilio, Laura,Sack, David A,Ali, Mohammad,Lessler, Justin,Luquero, Francisco J,Azman, Andrew Elsevier Science ;, The Lancet Pub. Group 2017 LANCET INFECTIOUS DISEASES Vol.17 No.10
<P><B>Summary</B></P><P><B>Background</B></P><P>Killed whole-cell oral cholera vaccines (kOCVs) are becoming a standard cholera control and prevention tool. However, vaccine efficacy and direct effectiveness estimates have varied, with differences in study design, location, follow-up duration, and vaccine composition posing challenges for public health decision making. We did a systematic review and meta-analysis to generate average estimates of kOCV efficacy and direct effectiveness from the available literature.</P><P><B>Methods</B></P><P>For this systematic review and meta-analysis, we searched PubMed, Embase, Scopus, and the Cochrane Review Library on July 9, 2016, and ISI Web of Science on July 11, 2016, for randomised controlled trials and observational studies that reported estimates of direct protection against medically attended confirmed cholera conferred by kOCVs. We included studies published on any date in English, Spanish, French, or Chinese. We extracted from the published reports the primary efficacy and effectiveness estimates from each study and also estimates according to number of vaccine doses, duration, and age group. The main study outcome was average efficacy and direct effectiveness of two kOCV doses, which we estimated with random-effect models. This study is registered with PROSPERO, number CRD42016048232.</P><P><B>Findings</B></P><P>Seven trials (with 695 patients with cholera) and six observational studies (217 patients with cholera) met the inclusion criteria, with an average two-dose efficacy of 58% (95% CI 42–69, <I>I</I><SUP>2</SUP>=58%) and effectiveness of 76% (62–85, <I>I</I><SUP>2</SUP>=0). Average two-dose efficacy in children younger than 5 years (30% [95% CI 15–42], <I>I</I><SUP>2</SUP>=0%) was lower than in those 5 years or older (64% [58–70], <I>I</I><SUP>2</SUP>=0%; p<0·0001). Two-dose efficacy estimates of kOCV were similar during the first 2 years after vaccination, with estimates of 56% (95% CI 42–66, <I>I</I><SUP>2</SUP>=45%) in the first year and 59% (49–67, <I>I</I><SUP>2</SUP>=0) in the second year. The efficacy reduced to 39% (13 to 57, <I>I</I><SUP>2</SUP>=48%) in the third year, and 26% (−46 to 63, <I>I</I><SUP>2</SUP>=74%) in the fourth year.</P><P><B>Interpretation</B></P><P>Two kOCV doses provide protection against cholera for at least 3 years. One kOCV dose provides at least short-term protection, which has important implications for outbreak management. kOCVs are effective tools for cholera control.</P><P><B>Funding</B></P><P>The Bill & Melinda Gates Foundation.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
